See more : Danske Invest Mix Offensiv (DKIMOAK.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Accuray Incorporated (ARAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accuray Incorporated, a leading company in the Medical – Specialties industry within the Healthcare sector.
- Fresenius SE & Co. KGaA (FSNUF) Income Statement Analysis – Financial Results
- Siemens Gamesa Renewable Energy, S.A. (GTQ1.DE) Income Statement Analysis – Financial Results
- Corsair Partnering Corporation (CORS-UN) Income Statement Analysis – Financial Results
- Ceres Global Ag Corp. (CRP.TO) Income Statement Analysis – Financial Results
- Chesapeake Energy Corporation (CHK) Income Statement Analysis – Financial Results
Accuray Incorporated (ARAY)
About Accuray Incorporated
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 446.55M | 447.61M | 429.91M | 396.29M | 382.93M | 418.79M | 404.90M | 383.41M | 398.80M | 379.80M | 369.42M | 315.97M | 409.22M | 222.28M | 221.63M | 233.60M | 210.38M | 140.45M | 52.90M | 22.38M | 19.57M | 2.71M | 19.35M |
| Cost of Revenue | 303.63M | 293.65M | 269.95M | 236.78M | 233.06M | 256.13M | 243.20M | 242.07M | 240.09M | 234.40M | 226.62M | 218.33M | 271.95M | 115.04M | 117.61M | 118.31M | 103.43M | 60.41M | 27.49M | 11.12M | 0.00 | 3.03M | 0.00 |
| Gross Profit | 142.92M | 153.96M | 159.96M | 159.51M | 149.87M | 162.65M | 161.70M | 141.34M | 158.71M | 145.40M | 142.80M | 97.64M | 137.27M | 107.24M | 104.02M | 115.29M | 106.95M | 80.04M | 25.41M | 11.26M | 19.57M | -317.00K | 19.35M |
| Gross Profit Ratio | 32.01% | 34.40% | 37.21% | 40.25% | 39.14% | 38.84% | 39.93% | 36.86% | 39.80% | 38.28% | 38.66% | 30.90% | 33.54% | 48.25% | 46.93% | 49.35% | 50.84% | 56.99% | 48.03% | 50.33% | 100.00% | -11.70% | 100.00% |
| Research & Development | 49.73M | 57.13M | 57.75M | 52.73M | 49.78M | 56.49M | 57.25M | 49.92M | 56.65M | 55.75M | 53.72M | 66.20M | 87.11M | 41.69M | 31.52M | 35.99M | 32.88M | 26.78M | 17.79M | 11.66M | 0.00 | 5.84M | 0.00 |
| General & Administrative | 50.07M | 48.27M | 44.39M | 41.72M | 40.97M | 49.58M | 48.14M | 43.77M | 50.12M | 46.38M | 45.34M | 57.73M | 58.60M | 56.66M | 35.47M | 36.22M | 32.28M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 42.62M | 46.18M | 49.66M | 42.82M | 47.25M | 56.00M | 60.11M | 57.48M | 56.81M | 62.44M | 61.89M | 54.37M | 54.55M | 37.18M | 34.19M | 45.49M | 42.73M | 37.89M | 0.00 | 0.00 | 0.00 | 6.71M | 0.00 |
| SG&A | 92.69M | 94.45M | 94.06M | 84.54M | 88.22M | 105.58M | 108.24M | 101.24M | 106.93M | 108.82M | 107.22M | 112.10M | 113.15M | 93.84M | 69.66M | 81.72M | 75.01M | 61.80M | 41.11M | 24.49M | 0.00 | 6.71M | 0.00 |
| Other Expenses | 0.00 | -11.74M | -10.39M | -27.67M | -6.70M | -14.93M | -19.22M | -18.72M | -18.30M | -18.62M | -14.22M | -13.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.02M | -24.75M |
| Operating Expenses | 142.42M | 151.58M | 151.81M | 137.27M | 138.00M | 162.07M | 165.49M | 151.16M | 163.59M | 164.57M | 160.94M | 178.30M | 200.26M | 135.53M | 101.18M | 117.71M | 107.89M | 88.58M | 58.90M | 36.15M | 0.00 | 15.57M | -24.75M |
| Cost & Expenses | 446.05M | 445.22M | 421.76M | 374.05M | 371.06M | 418.20M | 408.69M | 393.24M | 403.67M | 398.97M | 387.56M | 396.63M | 472.21M | 250.57M | 218.79M | 236.02M | 211.32M | 148.99M | 86.39M | 47.26M | 0.00 | 18.60M | -24.75M |
| Interest Income | 0.00 | 10.63M | 8.13M | 16.89M | 18.08M | 15.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 360.00K | 543.00K | 1.00K | 3.08M | 7.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.62M | 10.63M | 8.13M | 16.89M | 18.08M | 15.08M | 14.96M | 17.30M | 17.46M | 16.52M | 14.29M | 10.38M | 7.81M | 23.00K | 32.00K | 10.00K | 173.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.91M | 4.53M | 5.51M | 6.39M | 7.54M | 10.49M | 9.73M | 18.00M | 18.30M | 19.49M | 20.56M | 25.56M | 32.59M | 7.57M | 7.12M | 6.65M | 7.69M | 6.25M | 3.81M | 2.08M | 0.00 | 0.00 | 24.75M |
| EBITDA | 5.71M | 9.61M | 13.66M | 28.62M | 20.08M | 11.07M | 1.67M | 6.80M | 12.59M | -1.78M | 2.49M | -57.85M | -35.46M | -18.43M | 9.99M | 7.33M | 14.11M | 1.39M | -29.69M | -22.80M | 19.57M | -15.89M | 19.35M |
| EBITDA Ratio | 1.28% | 0.53% | 1.90% | 5.61% | 3.10% | 0.14% | -0.94% | -2.56% | -1.22% | -5.05% | -4.91% | -25.53% | -12.25% | -9.08% | 1.28% | -1.04% | 3.21% | -1.36% | -56.12% | -101.90% | 100.00% | -586.20% | 100.00% |
| Operating Income | 504.00K | 2.38M | 2.64M | 15.85M | 4.33M | -9.91M | -3.80M | -9.82M | -4.87M | -19.17M | -18.14M | -80.66M | -62.99M | -28.28M | 2.84M | -2.42M | -934.00K | -8.54M | -33.49M | -24.88M | 19.57M | -15.89M | -5.40M |
| Operating Income Ratio | 0.11% | 0.53% | 0.61% | 4.00% | 1.13% | -2.37% | -0.94% | -2.56% | -1.22% | -5.05% | -4.91% | -25.53% | -15.39% | -12.72% | 1.28% | -1.04% | -0.44% | -6.08% | -63.32% | -111.20% | 100.00% | -586.20% | -27.89% |
| Total Other Income/Expenses | -12.32M | -9.17M | -10.15M | -26.79M | -6.85M | -14.93M | -19.22M | -18.72M | -18.30M | -18.62M | -14.22M | -13.13M | -12.87M | 2.29M | 1.00K | 3.08M | 7.18M | 3.53M | 56.00K | -238.00K | -19.57M | 46.00K | -399.00K |
| Income Before Tax | -11.82M | -6.79M | -2.00M | -4.56M | 5.02M | -14.34M | -23.02M | -28.54M | -23.17M | -37.79M | -32.36M | -93.79M | -75.86M | -26.00M | 2.84M | 664.00K | 6.25M | -5.01M | -33.44M | -25.12M | 0.00 | -15.84M | -5.80M |
| Income Before Tax Ratio | -2.65% | -1.52% | -0.47% | -1.15% | 1.31% | -3.43% | -5.69% | -7.44% | -5.81% | -9.95% | -8.76% | -29.68% | -18.54% | -11.69% | 1.28% | 0.28% | 2.97% | -3.57% | -63.21% | -112.26% | 0.00% | -584.50% | -29.95% |
| Income Tax Expense | 3.73M | 2.49M | 3.35M | 1.75M | 1.86M | 2.09M | 878.00K | 1.04M | 2.34M | 2.42M | 3.09M | 3.57M | 2.60M | 1.12M | -4.00K | 55.00K | 867.00K | 1.44M | 258.00K | 68.00K | 11.70M | 0.00 | -5.80M |
| Net Income | -15.55M | -9.28M | -5.35M | -6.31M | 3.83M | -16.43M | -23.90M | -29.58M | -25.50M | -40.21M | -35.45M | -103.22M | -72.04M | -26.68M | 2.84M | 609.00K | 5.38M | -5.62M | -33.69M | -25.19M | -11.70M | -15.84M | 0.00 |
| Net Income Ratio | -3.48% | -2.07% | -1.24% | -1.59% | 1.00% | -3.92% | -5.90% | -7.71% | -6.40% | -10.59% | -9.60% | -32.67% | -17.60% | -12.00% | 1.28% | 0.26% | 2.56% | -4.00% | -63.70% | -112.57% | -59.77% | -584.50% | 0.00% |
| EPS | -0.16 | -0.10 | -0.06 | -0.07 | 0.04 | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 | 0.05 | 0.01 | 0.10 | -0.18 | -2.11 | -1.76 | -1.00 | -1.49 | -1.21 |
| EPS Diluted | -0.16 | -0.10 | -0.06 | -0.07 | 0.04 | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 | 0.05 | 0.01 | 0.09 | -0.18 | -2.11 | -1.76 | -1.00 | -1.49 | -1.21 |
| Weighted Avg Shares Out | 98.27M | 94.88M | 92.10M | 92.03M | 89.87M | 87.47M | 84.89M | 82.50M | 80.51M | 78.28M | 75.42M | 73.20M | 70.89M | 60.09M | 57.56M | 55.41M | 54.53M | 30.76M | 16.00M | 14.28M | 11.74M | 10.61M | 10.56M |
| Weighted Avg Shares Out (Dil) | 98.27M | 94.88M | 92.10M | 92.03M | 90.62M | 87.47M | 84.89M | 82.50M | 80.51M | 78.28M | 75.80M | 73.28M | 70.89M | 60.09M | 60.19M | 58.73M | 60.43M | 30.76M | 16.00M | 14.28M | 11.74M | 10.61M | 10.56M |
With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
Accuray to Host Investor Day at ASTRO on October 3, 2023
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
Accuray Incorporated - Impressive Growth As Orders Expands
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
Source: https://incomestatements.info
Category: Stock Reports